Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts
Qing Chang(Ontario Institute for Cancer Research), David W. Hedley(Ontario Institute for Cancer Research)
Cited by 34
Related Papers
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
|British Journal of Cancer|2008|155
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
|British Journal of Cancer|2009|124
Suppression of the Hypoxia-Inducible Factor-1 Response in Cervical Carcinoma Xenografts by Proteasome Inhibitors
|Cancer Research|2007|58
Pharmacodynamic monitoring of BAY 43‐9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells
|Cytometry Part B Clinical Cytometry|2006|52
Single‐cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry
|International Journal of Cancer|2014|42